Two fundamental genetic mechanisms, activation of protooncogenes and inactivation of tumour-suppressor genes, appear to account for the genesis of most, if not all, human cancers. Consequently, DNA alterations in NSCLC have previously been found to occur at different chromosomal loci containing both oncogenes, such as ras (Rosell et al, 1993) , and tumour-suppressor genes, specifically p53 (Horio et al, 1993) . Alterations on short tandem repeat DNA non-codifying sequences (microsatellites) (Weber and May, 1989) are common in a gamut of human genetic disorders. Although the function of these tandem repeats is not yet clear, some researchers have speculated that such sequences may be targets for certain proteins, which play a major role in the regulation of gene expression and DNA recombination (Hamada et al, 1984; Berg et al, 1989) . Microsatellite instability can be witnessed as a change in the length of microsatellite sequences (expansions or contractions) in tumour DNA compared with constitutional DNA, but also as the complete loss of one or both alleles of the repeat locus (LOH).
RERs are common in lung cancer and mostly localized on chromosome 3p (Hibi et al, 1992; Shridhar et al, 1994; Wooster et al, 1994) , but can be found on chromosome 2p (Merlo et al, 1994) . This is a little reported phenomenon in lung cancer (Fong et al, 1995; Ryberg et al, 1995) , whereas widespread microsatellite instability commonly occurs in hereditary non-polyposis colorectal cancer (HNPCC) Thibodeau et al, 1993 ) and other sporadic tumours, i.e. colorectal, endometrial and gastric tumours Risinger et al, 1993; Mironov et al, 1994) . The tumour phenotype displaying frequent RERs (Peinado et al, 1992) , which is characteristic of the Lynch syndrome and reflects a defect in mismatch repair (Parsons et al, 1993) , is not observed to the same degree in other non-HNPCC tumours (Mao et al, 1994) , including lung cancer Merlo et al, 1994) .
Sixty-four NSCLC patients were evaluated for evidence of genomic instability at (CA)n dinucleotide repeats on chromosomes 5 (25) 2p and 3p with three microsatellite markers on chromosome 2p and five on chromosome 3p. Most of these microsatellite markers were chosen near or within regions containing mismatch repair genes, such as MSH2 on chromosome 2p and MLHI on chromosome 3p (Hemminki et al, 1994; Liu et al, 1994; Parsons et al, 1995) , or thought to contain some tumour-suppressor genes. Furthermore, mutations on K-ras and p53 genes were screened in order to establish plausible correlations between the presence or absence of mutations and microsatellite instability. Our findings suggest that RERs on microsatellite repeats located on chromosomes 2p and 3p are frequent in NSCLC and indicates that p53 mutations and RER changes are rare in the same NSCLC DNA samples, whereas certain K-ras genotypes tend to be linked to RER changes. The results of this study indicate that RERs may be prognostically useful in defining the risk of relapse in NSCLC patients.
MATERIALS AND METHODS Subjects
All 64 NSCLC patients had undergone thoracotomy and resection between 1990 and 1991 as treatment of their disease. This period was studied because post-operative adjuvant chemotherapy was not employed routinely with patients at that time. Thus, these NSCLCs represented a subset of lung tumours found in patients with operable disease [stage I-IIIA, according to the tumour-node-metastasis classification (Mountain, 1986) ]. There was no family history of hereditary non-polyposis colorectal cancer in any case studied. Of the 64 patients in this study, two were female and 62 were male with an average age of 61 years (range 40-75 years). The patients' main characteristics are summarized in Table 1 . Patients were seen at 3 month intervals during the first post-operative year, every 4 months during the second and third year, and every 6 months thereafter. Follow-up consisted of biochemical profile, chest radiograph and computerized tomographic scan, and physical examination. Data on lung cancer recurrence and causes of death were obtained.
DNA extraction
Microdissection of tumour and surrounding normal lung tissue from 10-jim histology sections was performed as previously described by McPherson et al (1991) . DNA was quantified by spectrophotometry and 100 ng of tissue were used in the polymerase chain reaction (PCR) analysis described below.
Analysis of microsatellite alterations
Microsatellite sequences are easy to assay using PCR (Jeffreys et al, 1988) . We performed a PCR assay using the corresponding primer pair for each microsatellite marker. Microsatellite markers analysed for each sample were D2S136 (2p4-pl3), D2S162 (2p25-p22) and D2S391 (2pl5) on chromosome 2p, and D3S1284 (3pl3-pl4), D3S1289 (3p2l.l-pl4.3), D3S1067 (3p2l.l-pl4. with an additional 3 min extension for cycle 35 on a DNA Thermal Cycler (Perkin Elmer Gene Amp PCR System 9600, Norwalk, CT, USA). The DNA generated by PCR was characterized by agarose gel electrophoresis. The PCR products were denatured by 96% formamide and run on a 6% polyacrylamide gel containing 8 M urea for 2-3 h at 40-45 W. The gels were dried and exposed to radiographic film (X-OMAT-AR, Kodak, USA).
Analysis of K-ras and p53 gene mutations Detection of mutations on K-ras oncogene was performed using a PCR-SSCP assay and by PCR-allele-specific oligonucleotide (ASO) hybridization to determine specific point mutations. For the PCR-SSCP assay, PCR was performed using [OC32P]dCTP to label amplified products directly. Amplification of ras-specific sequences was performed as described (Rosell et al, 1993) . K-ras codons 12, 13 and 61 amplified radiolabelled products were electrophoresed through 6% non-denaturing acrylamide gels at 4°C for 10-15 h at 4 W. Dried gels were then exposed to radiographic films overnight at -80°C using intensifying screens. PCR-ASO hybridization assay was performed as previously described (Rosell et al, 1993) . Mutations in exons 5-8 of the p53 gene were analysed by means of PCR-SSCP using p53-specific primers. PCR-SSCP assay was performed as for K-ras gene, while dideoxy sequencing was as previously described (Sanger et al, 1977) .
Statistical analysis
The primary statistical outcome in this study was overall survival measured from the date of surgery. Survival curves were drawn for each group of different variables, using the Kaplan-Meier method (Kaplan and Meier, 1959) , and differences among the curves were computed by the log-rank statistic (Miller, 1981) . The association between RER-positive tumour DNAs and other genetic aberrations with clinicopathological features was assessed using the chisquare test. The most significant prognostic factors were identified by the Cox proportional hazard method (Cox, 1972) . The beta regression coefficients presented for the multivariate analyses indicate a relationship between a specific variable and overall survival with the positive coefficient denoting an increased risk of death and a negative coefficient denoting the opposite effect. All P-values were based on two-sided comparisons. P-values of less than 0.05 were considered to indicate statistical significance. Correlation with LOH at chromosomes 2p and 3p
We examined the association between the presence of RERs and LOH. Allelic loss was observed in 23 of the 64 tumour specimens (36%), at 6% of the loci screened. The incidence of LOH at the loci examined is shown in Table 2 . Overall, the frequency of 2p LOH and 3p LOH was not significantly different in RER-negative tumours (50%) in comparison with RER-positive tumours (28.5%) ( Table 3) .
Correlation with K-ras and p53 gene mutations RER occurred in combination with other genetic aberrations in this cohort of patients. The incidence of K-ras gene mutations was no different in RER-positive tumours (21%) than in RER-negative tumours (18%, P = 0.51), although differences surfaced in stage I, K-ras mutations according to specific genotypes at codon 12 (Rosell et al, 1993) . There was a trend in the RER-positive group to contain aspartic and serine substitutions instead of the wild-type glycine, which was not observed in the RER-negative group. Valine codon 12 mutations were commonly observed in RERnegative tumours but not seen in RER-positive tumours. In addition, p53 gene mutations were detected in 13 of 42 (31 %) RER-positive tumours and were higher in the RER-negative group (50%, curves was significant (P = 0.005) (Figure 2 ). Similar results were obtained when disease-free survival was the end point. Furthermore, in the group of patients with microsatellite alterations on more than two dinucleotide markers, there was still poorer outcome with no long-term survivors. To identify the most powerful prognostic factors, we performed multivariate analyses with Cox proportional hazards model. The hazards ratios were calculated using two models with clinicopathological factors interrelated with K-ras and p53 gene mutations, LOH and RER phenotype. The first model combined tumour stage, histology, K-ras and p53 mutations, LOH and RER presence or absence. The second model combined tumour stage and RER phenotype because the combination gave the best fit attainable with any of the prognostic factors combination (Table 4 ). The presence of RER yielded a hazard ratio of 2.89 (95% confidence interval, 2.23-3.79; P = 0.002). On the other hand, patients with LOH-positive tumours also tended to show a worse outcome, but these results did not reach statistical significance (P = 0.07).
DISCUSSION
The main objectives of this study were to determine whether patients with NSCLC had frequent microsatellite instability of (CA)n repeats on chromosomes 2p and 3p and to explore the importance of RER phenotype as a prognostic marker in resected NSCLC. Most patients in this study (66%) showed RER in at least one of the eight dinucleotide repeat markers examined. Recent cytogenetic and molecular studies have elucidated the fragility of chromosome 3p in a number of primary NSCLC tumours as well as in small-cell lung cancer (SCLC) (Hibi et al, 1992; Horio et al, 1993; Ryberg et al, 1995) . Shridhar et al (1994) have documented frequent RERs (13 of 38, 34%) in NSCLC tumours using ten microsatellite markers on chromosome 3p. These findings are strikingly different from a former study in which RERs were present in only 2% of 86 lung tumours analysed . This low frequency could be attributed to the fact that only one of the eight microsatellite markers screened was derived from chromosome 3, D3S1266 (3p24-p25). On reassessing the microsatellite instability of these patients using four different markers from chromosome 3p, 21 % were found to have changes in at least one microsatellite locus (Ryberg et al, 1995) . In a recent study (Fong et al, 1995) , RER was also an infrequent event, affecting only seven of 108 lung tumours (6.5%), reflecting once more the fact that no microsatellite markers on chromosome 3p were tested and only one on chromosome 2p. Ryberg et al (1995) have shown that there are several factors that may influence the frequency of the NSCLC microsatellite instability found, such as the number of loci studied and their location, as well as the selection of patients. This confers the ability to induce microsatellite instability to factors other than mismatch repair defects defined in HNPCC, at least as far as chromosome 3p in lung cancer is concerned. In this study, as in SCLC (Merlo et al, 1994) , we found that microsatellites markers analysed on chromosome 2p were frequent targets for RER in this kind of tumour. These results indicate that the RER phenomenon is not as widespread in NSCLC as it is in tumours from HNPCC kindreds, and that both chromosomes 2p and 3p may be hotspots for RER in lung cancer. One or several tumour-suppressor genes potentially able to alter microsatellite stability may be harboured on these chromosome arms. Genetic instability is likely to increase the activation of loci, which directly contribute to tumorigenesis (Loeb, 1994) , although p53 or K-ras do not appear to be among these loci. p53 mutations and the presence of RER, revealed by (CA)n repeat alterations, act through distinct pathways, since these changes are not observed simultaneously in the same tumour, as described in gastric cancer (Mironov et al, 1994) and in the present NSCLC study. Our patients with stage I RER tumours had a significantly higher p53 rate without mutations than did those with RER-negative tumours (81 % vs 45%). Surprisingly, a worse outcome was seen in patients without p53 mutations when compared with patients whose tumours had p53 mutations. This biological behaviour could be explained partly by the higher rate of RER-positive tumours in those without p53 mutations, indicating that some other factors intimately related to RER could confer higher aggressiveness to NSCLCs. These findings concur with the data of other authors (Ryberg et al, 1994) , who found no correlation between p53 mutations and the presence of rare alleles; the latter related to a higher incidence of microsatellite instability (Ryberg et al, 1995) . The prevalence of K-ras mutations was not significantly different according to RER phenotype. However, in patients with stage I RER-positive tumours, there was a tendency to have aspartic and serine codon 12 K-ras mutations, which are said to confer more tumour aggressiveness (Rosell et al, 1994) , while valine codon 12 mutations, which have less virulent behaviour, were linked to stage I RER-negative tumours, although the differences were not significant.
This particular type of genetic error may well result from defective DNA repair genes located on chromosomes 2p and 3p (MSH2 and MLHI), possibly along with other similar genes (Hemminki et al, 1994; Liu et al, 1994; Parsons et al, 1995; Gleeson et al, 1996) . However, other investigators have defined novel mechanisms involving greater repetitive DNA regions (variable number of tandem repeats), such as the presence of rare constitutional alleles of the H-ras I minisatellite locus, which are linked to a higher risk of developing cancer (Krontiris et al, 1993; Ryberg et al, 1995) . Moreover, mechanisms involving cell oxidative stress in mismatch repair system failure have also been suggested (Brentnall et al, 1995) , indicating deficient pathways other than mismatch repair gene defects.
To our knowledge, this is the first study in which survival analysis has been carried out according to RER phenomenon in NSCLC and our data indicate firstly, that, RER occurs frequently in NSCLC (66%) and, secondly, that RER-positive tumours are linked to worse survival and may be an independent predictor of poor outcome in NSCLC patients who undergo surgery. In addition, the presence of RERs is not related to p53 mutations and the absence of the prognostic value of p53 mutations suggests that other undetected changes in RER tumours may be implicated in NSCLC. Furthermore, the relatively high proportion of patients with RER-positive tumours who have no LOH or K-ras mutations prompts us to propose that RERs could be a new relevant prognostic marker in the early stages of NSCLC.
